Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sanofi (GB:0O59)
LSE:0O59
Sanofi (0O59) Share Forecast & Price Target
8 Followers
See the Price Targets and Ratings of:
0O59 Analyst Ratings
Moderate Buy
7 Buy
3 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0O59 Stock 12 Month Forecast
Average Price Target
€106.08
▲(36.46% Upside)
| Highest Price Target€125.35 | Average Price Target€106.08 | Lowest Price Target€80.23 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
DZ BANK AG
Reiterated
07/26/24
Jefferies
Reiterated
07/25/24
Bank of America Securities
Reiterated
07/25/24
Kepler Capital
Reiterated
07/25/24
J.P. Morgan
Reiterated
07/16/24
Guggenheim
Reiterated
07/11/24
Deutsche Bank
Reiterated
07/10/24
Stifel Nicolaus
Reiterated
07/08/24
Berenberg Bank
Reiterated
07/01/24
Leerink Partners
€100
Buy
€100.00
(28.65% Upside)
Reiterated
06/28/24
We are tweaking our model ahead of SAN FP’s 2Q24 earnings results on Jul. 25, but our estimates remain essentially unchanged. We slightly lowered our 2Q24E rev 1% from €11.1B to €11.0B (cons. is €11.1B) but increased our 2Q24E adj. basic EPS 1% from €1.64 to €1.66 (cons. is €1.63) due to lower R&D costs given SOBI (Not Rated) reimbursement of $180-200 USD (roughly €168-187 at current FX). Our 2024E total rev is essentially unchanged at €48.3B (cons. is €48.3B) and our 2024E adj. dil. EPS increased 1% from €7.65 to €7.72 (cons. is €7.59). We continue to rate SAN FP shares OP with a €100 PT (12.0x our ‘25E adj. dil. EPS of €8.37). Next key catalyst is potential FDA approval of Beyfortus’ (RSV antibody for infants) additional US manufacturing lines this summer; if it is approved, SAN FP could beat its 2024 target of €1B.
Barclays
€105
Buy
€105.00
(35.08% Upside)
Reiterated
04/04/24
Barclays Sticks to Its Buy Rating for Sanofi (SNYNF)
Morgan Stanley
€50.65
Hold
€50.65
(-34.84% Downside)
Reiterated
01/23/24
Morgan Stanley starts Sanofi-Aventis (SNY) at EqualweightMorgan Stanley analyst Mark Purcell initiates coverage on Sanofi-Aventis (NASDAQ: SNY) with a Equalweight rating and a price target of $55.00.
Wolfe Research
€105
Buy
€105.00
(35.08% Upside)
Upgraded
01/03/24
Sanofi upgraded to Outperform from Peer Perform at Wolfe ResearchSanofi upgraded to Outperform from Peer Perform at Wolfe Research
Citi
€138→€125
Buy
€125.00
(60.81% Upside)
Reiterated
10/31/23
Sanofi (SAN:FP) (SNY) PT Lowered to EUR125 at CitiCiti analyst Peter Verdult lowered the price target on Sanofi (SAN:FP) (NASDAQ: SNY) to EUR125.00 (from EUR138.00) while maintaining a Buy rating.
Best Analysts Covering Sanofi
Which Analyst Should I Follow If I Want to Buy GB:0O59 and Sell After:
1 Month
xxx
Success Rate
12/18 ratings generated profit
Average Return
-0.22%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of -0.22% per trade.
3 Months
xxx
Success Rate
12/17 ratings generated profit
Average Return
+1.62%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.59% of your transactions generating a profit, with an average return of +1.62% per trade.
1 Year
Success Rate
14/18 ratings generated profit
Average Return
+5.70%
reiterated a buy rating 12 months ago
Copying Dominic Lunn's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +5.70% per trade.
2 Years
xxx
Success Rate
28/36 ratings generated profit
Average Return
+7.61%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +7.61% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
0O59 Analyst Recommendation Trends
Rating
Mar 24
Apr 24
May 24
Jun 24
Jul 24
Strong Buy
0
0
0
0
0
Buy
21
21
19
20
19
Hold
12
11
7
7
7
Sell
4
4
2
3
3
Strong Sell
0
0
0
0
0
total
37
36
28
30
29
Each month's total comprises the sum of three months' worth of ratings.
0O59 Financial Forecast
0O59 Stock Forecast FAQ
What is GB:0O59’s average 12-month price target, according to analysts?
Based on analyst ratings, Sanofi’s 12-month average price target is €106.08.
What is GB:0O59’s upside potential, based on the analysts’ average price target?
Sanofi has 36.46% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Sanofi a Buy, Sell or Hold?
Sanofi has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 3 hold ratings and 1 sell ratings.
What is Sanofi’s share price target?
The average share price target for Sanofi is €106.08. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €125.35 ,and the lowest forecast is €80.23. The average share price target represents 36.46% Increase from the current price of €77.733.
The highest analyst share price target is €125.35 ,and the lowest forecast is €80.23. The average share price target represents 36.46% Increase from the current price of €77.733.
What do analysts say about Sanofi?
Sanofi’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of Sanofi?
To buy shares of GB:0O59, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.